• Member Login
  • Become a Member
  • Database Search
IATI - Israel Advanced Technology Industries
IATI - Israel Advanced Technology Industries
IATI News & Events Daily Industry News First Breast Cancer Patients Treated With Israeli Minimally Invasive Cryoablation Procedure

First Breast Cancer Patients Treated With Israeli Minimally Invasive Cryoablation Procedure

Jun. 4, 2012  | by Aviva Mishmari

IceCure Medical Ltd. announced the first four breast cancer patients treated with the IceSense3™ Cryoablation Procedure in Japan. The IceSense3 System was used to treat small breast cancer tumors in a minimally invasive procedure using ultrasound guidance and local anesthesia. These patients were the first four enrolled in a clinical trial of 30 small, early stage breast cancer patients at Kameda Medical Center in Kamogawa City, Japan.

Cryoablation has been used for years to treat both malignant and benign tumors in the body. This new system from IceCure Medical has been developed specifically for breast tumors, and can be performed comfortably with ultrasound guidance. The system uses extremely cold temperatures to destroy (ablate) breast tumors. An attractive alternative to open surgery, the IceSense3 procedure takes place in a physician's office or breast center, and doesn't require sutures or general anesthesia. The system is currently being used worldwide for treatment of fibroadenomas, benign breast tumors, and holds promise as a potential treatment option for malignant breast tumors.

IceCure Medical Ltd. is a medical device company (TASE: ICCM) focused on developing and marketing minimally invasive, office-based cryoablation treatment solutions for women's tumors. The proprietary IceSense3™ Cryoablation System offers a comfortable, ultrasound-guided procedure to treat breast tumors. The company was founded in 2006 with main offices in Caesarea, Israel and U.S. headquarters in Cleveland, Ohio.

For the full news release, see:


| Terms of Use | Privacy Policy | Sitemap